Search for: "Sanofi"
Results 141 - 160
of 1,196
Sort by Relevance
|
Sort by Date
26 Mar 2023, 9:15 am
Sanofi, a case with the parties and 27 Amici, including the United States, weighing in on whether and how the Court should address the enablement requirement of Section 112 in the context of genus claims, and in particular, genus claims to antibodies in the pharmaceutical sciences. [read post]
26 Mar 2023, 9:15 am
Sanofi, a case with the parties and 27 Amici, including the United States, weighing in on whether and how the Court should address the enablement requirement of Section 112 in the context of genus claims, and in particular, genus claims to antibodies in the pharmaceutical sciences. [read post]
23 Mar 2023, 11:41 am
Sanofi claims that what Amgen did in this case was “claim a lot and disclose a little. [read post]
21 Mar 2023, 8:17 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
20 Mar 2023, 7:52 am
” The BMS Vice President for the “Sanofi Alliance” at the time wrote: “Sanofi remains adverse [sic] to doing any further work on either aspirin or clopidogrel resistance because of the potential negative marketing implications. [read post]
19 Mar 2023, 9:32 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
14 Mar 2023, 8:58 pm
Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure decisions, in this case enablement under 35 U.S.C. [read post]
12 Mar 2023, 8:43 pm
Sanofi. [read post]
12 Mar 2023, 9:15 am
The brief responds to arguments raised both by rival pharmaceutical firm Sanofi and the U.S. federal government in Amgen’s appeal of the invalidation of its patent claims as a matter of law under 35 U.S.C. [read post]
12 Mar 2023, 9:15 am
The brief responds to arguments raised both by rival pharmaceutical firm Sanofi and the U.S. federal government in Amgen’s appeal of the invalidation of its patent claims as a matter of law under 35 U.S.C. [read post]
7 Mar 2023, 9:16 pm
Sanofi may be the most closely watched patent case since AMP v. [read post]
7 Mar 2023, 8:33 pm
Sanofi focuses on a broadly claimed genus and asks whether the disclosure is sufficiently detailed. [read post]
6 Mar 2023, 5:06 am
Sanofi-Aventis U.S. [read post]
1 Mar 2023, 6:09 am
The following is a really wonderful Guest Post from UC San Francisco Law School Professor Jeffrey Lefstin focusing on a recent ITC decision finding a claimed drill bit abstract because of its functional limitations. [read post]
1 Mar 2023, 4:15 am
Sanofi on March 27. [read post]
1 Mar 2023, 4:15 am
Sanofi on March 27. [read post]
19 Feb 2023, 9:16 pm
Sanofi"). [read post]
15 Feb 2023, 6:21 am
The case is remitted to the opposition division with the order to maintain the patent on the basis of auxiliary request 1 filed with the statement of grounds of appeal dated 24 October 2019 and a description to be adapted thereto.This decision T 2303/19 (Stabilization of vaccines by lyophilization/ SANOFI) of 7.12.2022 (pdf) has European Case Law Identifier: ECLI:EP:BA:2022:T230319.20221207. [read post]
12 Feb 2023, 9:15 am
Sanofi, a closely-watched case that will consider the scope of the enablement inquiry under 35 U.S.C. [read post]
12 Feb 2023, 9:15 am
Sanofi, a closely-watched case that will consider the scope of the enablement inquiry under 35 U.S.C. [read post]
